Leerink Partnrs Issues Positive Estimate for Natera Earnings

Natera, Inc. (NASDAQ:NTRA - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for Natera in a report issued on Wednesday, November 13th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of ($1.61) per share for the year, up from their previous estimate of ($1.83). The consensus estimate for Natera's current full-year earnings is ($1.96) per share. Leerink Partnrs also issued estimates for Natera's Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.40) EPS.

Other analysts have also issued research reports about the stock. Robert W. Baird lifted their price objective on shares of Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research report on Wednesday. Leerink Partners lifted their price objective on shares of Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. TD Cowen lifted their price objective on shares of Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a research report on Wednesday. Sanford C. Bernstein lifted their price objective on shares of Natera from $125.00 to $135.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Natera from $135.00 to $160.00 and gave the company an "overweight" rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Natera presently has a consensus rating of "Moderate Buy" and a consensus price target of $137.65.

Natera Stock Down 3.3 %

Shares of NASDAQ NTRA traded down $5.05 during mid-day trading on Friday, reaching $146.06. 2,242,126 shares of the company's stock traded hands, compared to its average volume of 1,338,689. The stock has a market cap of $19.28 billion, a P/E ratio of -82.99 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.01. Natera has a 1-year low of $52.01 and a 1-year high of $167.79. The business has a 50-day simple moving average of $127.38 and a 200 day simple moving average of $115.46.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analysts' expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business's revenue was up 63.9% on a year-over-year basis. During the same period last year, the company earned ($0.95) earnings per share.

Hedge Funds Weigh In On Natera

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC grew its stake in Natera by 1,073.1% in the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company's stock worth $7,118,000 after buying an additional 60,127 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Natera by 15.1% in the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company's stock valued at $6,810,000 after purchasing an additional 9,781 shares in the last quarter. Natixis purchased a new stake in shares of Natera in the 1st quarter valued at $758,000. Chartwell Investment Partners LLC boosted its stake in shares of Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company's stock valued at $5,243,000 after purchasing an additional 11,362 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft purchased a new stake in shares of Natera in the 2nd quarter valued at $478,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insider Buying and Selling

In other Natera news, insider Jonathan Sheena sold 2,700 shares of the business's stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total value of $344,439.00. Following the completion of the transaction, the insider now owns 284,741 shares of the company's stock, valued at $36,324,409.37. The trade was a 0.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Burkes Brophy sold 1,866 shares of the business's stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $126.45, for a total transaction of $235,955.70. Following the completion of the transaction, the chief financial officer now directly owns 68,851 shares of the company's stock, valued at approximately $8,706,208.95. This represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,881 shares of company stock valued at $3,733,983. Company insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.